Zevra Therapeutics Receives the US FDA’s Approval of Miplyffa (Arimoclomol Citrate) for Treating Niemann-Pick Disease Type C (NPC)
Shots:
-
The US FDA has awarded priority review voucher & approved Miplyffa (47mg to 124mg, oral, TID) + miglustat to treat neurological manifestations in adults & pediatrics (≥2yrs.) with NPC, with its launch planned within 8-12wks.
-
Approval was based on trial of Miplyffa + miglustat vs PBO in NPC patients (2-19yrs.), showing halted disease progression with 0.2 vs 1.9-point reduction at 12mos. Data from a 48mos. OLE trial provided additional evidence of improved outcomes
-
Zevra has launched AmplifyAssist, offering insurance education, copay assistance, disease information, therapy management counseling & support for prescription refills for the eligible patients in need
Ref: Zevra Therapeutics | Image: Zevra Therapeutics
Related News:- Zevra Therapeutics Resubmits Arimoclomol’s NDA to the US FDA for Treating Niemann-Pick disease Type C (NPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
